166 related articles for article (PubMed ID: 12512391)
1. Regulators of apoptosis as anticancer targets.
Tolcher AW
Hematol Oncol Clin North Am; 2002 Oct; 16(5):1255-67. PubMed ID: 12512391
[TBL] [Abstract][Full Text] [Related]
2. TRAIL/Apo-2L: mechanisms and clinical applications in cancer.
Srivastava RK
Neoplasia; 2001; 3(6):535-46. PubMed ID: 11774036
[TBL] [Abstract][Full Text] [Related]
3. Modulation of death receptor pathways in oncology.
de Vries EG; Timmer T; Mulder NH; van Geelen CM; van der Graaf WT; Spierings DC; de Hooge MN; Gietema JA; de Jong S
Drugs Today (Barc); 2003; 39 Suppl C():95-109. PubMed ID: 14988748
[TBL] [Abstract][Full Text] [Related]
4. Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells.
Taniai M; Grambihler A; Higuchi H; Werneburg N; Bronk SF; Farrugia DJ; Kaufmann SH; Gores GJ
Cancer Res; 2004 May; 64(10):3517-24. PubMed ID: 15150106
[TBL] [Abstract][Full Text] [Related]
5. Apoptosis and cancer: when BAX is TRAILing away.
Roth W; Reed JC
Nat Med; 2002 Mar; 8(3):216-8. PubMed ID: 11875486
[No Abstract] [Full Text] [Related]
6. Apoptosis-based therapies and drug targets.
Fischer U; Schulze-Osthoff K
Cell Death Differ; 2005 Aug; 12 Suppl 1():942-61. PubMed ID: 15665817
[TBL] [Abstract][Full Text] [Related]
7. TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer.
Cretney E; Shanker A; Yagita H; Smyth MJ; Sayers TJ
Immunol Cell Biol; 2006 Feb; 84(1):87-98. PubMed ID: 16405656
[TBL] [Abstract][Full Text] [Related]
8. Hot on the TRAIL of acute promyelocytic leukemia.
Zelent A
Nat Med; 2001 Jun; 7(6):662-4. PubMed ID: 11385499
[No Abstract] [Full Text] [Related]
9. TRAIL receptor signalling and modulation: Are we on the right TRAIL?
Mahalingam D; Szegezdi E; Keane M; de Jong S; Samali A
Cancer Treat Rev; 2009 May; 35(3):280-8. PubMed ID: 19117685
[TBL] [Abstract][Full Text] [Related]
10. Promoting apoptosis as a strategy for cancer drug discovery.
Fesik SW
Nat Rev Cancer; 2005 Nov; 5(11):876-85. PubMed ID: 16239906
[TBL] [Abstract][Full Text] [Related]
11. Pathways involved in proliferating, senescent and immortalized keratinocyte cell death mediated by two different TRAIL preparations.
Qin JZ; Bacon PE; Chaturvedi V; Bonish B; Nickoloff BJ
Exp Dermatol; 2002 Dec; 11(6):573-83. PubMed ID: 12473065
[TBL] [Abstract][Full Text] [Related]
12. [Current concepts on apoptotic signalling pathways: new targets for anticancer strategies].
Ségal-Bendirdjian E; Hillion J; Belmokhtar CA
Bull Cancer; 2003 Jan; 90(1):9-17. PubMed ID: 12609799
[TBL] [Abstract][Full Text] [Related]
13. Galectin-1 Modulates the Survival and Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Sensitivity in Human Hepatocellular Carcinoma Cells.
Li J; Sun RR; Yu ZJ; Liang H; Shen S; Kan Q
Cancer Biother Radiopharm; 2015 Oct; 30(8):336-41. PubMed ID: 26348206
[TBL] [Abstract][Full Text] [Related]
14. TRAIL: a potential agent for cancer therapy.
Shi J; Zheng D; Man K; Fan ST; Xu R
Curr Mol Med; 2003 Dec; 3(8):727-36. PubMed ID: 14682494
[TBL] [Abstract][Full Text] [Related]
15. Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents.
Rowinsky EK
J Clin Oncol; 2005 Dec; 23(36):9394-407. PubMed ID: 16361639
[TBL] [Abstract][Full Text] [Related]
16. The differential sensitivity of Bc1-2-overexpressing human breast tumor cells to TRAIL or doxorubicin-induced apoptosis is dependent on Bc1-2 protein levels.
Ruiz de Almodóvar C; Ruiz-Ruiz C; Muñoz-Pinedo C; Robledo G; López-Rivas A
Oncogene; 2001 Oct; 20(48):7128-33. PubMed ID: 11704839
[TBL] [Abstract][Full Text] [Related]
17. Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL.
Altucci L; Rossin A; Raffelsberger W; Reitmair A; Chomienne C; Gronemeyer H
Nat Med; 2001 Jun; 7(6):680-6. PubMed ID: 11385504
[TBL] [Abstract][Full Text] [Related]
18. Concepts in the use of TRAIL/Apo2L: an emerging biotherapy for myeloma and other neoplasias.
Mitsiades N; Mitsiades CS; Poulaki V; Anderson KC; Treon SP
Expert Opin Investig Drugs; 2001 Aug; 10(8):1521-30. PubMed ID: 11772267
[TBL] [Abstract][Full Text] [Related]
19. License to kill tumors: how much hope is justified for trail?
Frank S; Ebert AD
Curr Pharm Des; 2001 Nov; 7(16):1689-701. PubMed ID: 11562306
[TBL] [Abstract][Full Text] [Related]
20. The potential of TRAIL for cancer chemotherapy.
Nagane M; Huang HJ; Cavenee WK
Apoptosis; 2001 Jun; 6(3):191-7. PubMed ID: 11388668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
